October 22, 2024
Life sciences data giant IQVIA Inc. and competitor Veeva Systems Inc. slammed each other's summary judgment bids made public Tuesday in a trade secrets lawsuit in New Jersey federal court, with Veeva arguing that IQVIA's purported trade secrets are hardly confidential and IQVIA saying Veeva's assertions are "a last-ditch effort to avoid liability."
May 15, 2020
Pharmaceutical information technology company Veeva Systems Inc. on Friday slammed the sanctions bid by life sciences data giant IQVIA in trade secrets litigation, telling a New Jersey federal court Friday to reject IQVIA's "hyperbolic and groundless" allegation that Veeva destroyed evidence.
February 26, 2020
Pharmaceutical information technology company Veeva Systems Inc. has moved to update its antitrust monopoly claims with additional products that life sciences data giant IQVIA Inc. has allegedly refused access to.
February 19, 2020
Life sciences data giant IQVIA told a New Jersey federal court that pharmaceutical information technology company Veeva Systems destroyed evidence of its trade secrets theft and then lied about it, calling for sanctions that would end dueling claims in a simmering dispute.
August 19, 2019
Pharmaceutical information technology company Veeva Systems is pursuing antitrust claims on the wrong side of the country, life sciences data giant IQVIA told a California federal court last week, arguing that Veeva's new allegations over withheld data access are "virtually identical" to accusations already percolating in New Jersey.
October 04, 2018
A New Jersey federal judge has refused to dismiss pharmaceutical information technology company Veeva Systems Inc.'s monopoly claims in its countersuit against life sciences data giant IQVIA Inc., ruling Wednesday that it plausibly alleged IQVIA tried to block customer access to its product.
March 13, 2017
Veeva Systems Inc. lodged a countersuit Monday against Quintiles IMS Inc. in New Jersey federal court alleging anticompetitive conduct over the offering of software products to life sciences companies, the same day it sought partial dismissal of IMS' suit alleging Veeva misappropriated health care data trade secrets.